HR Execs on the Move

Metabiota

www.metabiota.com

 
Metabiota is the pioneer in comprehensive risk analytics that improve the world`s resilience to epidemics. Built on a strong foundation of epidemiology and international field science, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven insights that help countries, governments and corporations manage and mitigate infectious diseases. With a strategic global presence and sustained partnerships, Metabiota`s agile approach is helping the world track and transfer the risk associated with epidemic threats.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.metabiota.com
  • 425 California 2nd Floor
    San Francisco, CA USA 94104
  • Phone: 415.398.4712
  • Fax: 415.398.4716

Executives

Name Title Contact Details
Ben Oppenheim
Vice President, Product, Policy and Partnerships Profile

Similar Companies

Mobilion Systems

MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.

Access BIO

Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TAU Systems

TAU Systems is a deep-tech company developing the first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company. Led by premier experts in laser-driven particle accelerators, TAU is democratizing access for the progress of biotechnology, nuclear and more.

Hoffmann-La Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche

Inimmune

Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.